Cytochrome P450: Structure, mechanism, and biochemistry: Third edition

Cytochrome P450: Structure, Mechanism, and Biochemistry: Third edition

Volumn , Issue , 2005, Pages 1-689

  De Montellano, Paul R Ortiz ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892292579     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/b139087     Document Type: Book

References (250)

1. Sato, R. and T. Omura (eds) (1978). Cytochrome P450. Academic Press, New York, NY.
2. Sato, R., T. Omura, Y. Imai, and Y. Fujii-Kuriyama (eds) (1987). Cytochrome P450: New trends. Yamada Science Foundation, Japan.
3. Estabrook, R. W. and M. E. Pullman (eds) (1967). Methods in Enzymology, Volume 10: Oxidation and Phosphorylation. Academic Press, New York, NY.
4. Fleischer, S. and L. Packer (eds) (1978). Methods in Enzymology, Volume 52: Biological Oxidations, Microsomal cytochrome P450, and other hemoprotein systems. Academic Press, New York, NY.
5. Johnson, E. F. and M. R. Waterman (eds) (1991). Methods in Enzymology, Volume 206: Cytochrome P450, Part A. Academic Press, New York, NY.
6. Johnson, E. F. and M. R. Waterman (eds) (1996). Methods in Enzymology, Volume 272: Cytochrome P450, Part B. Academic Press, New York, NY.
7. Johnson, E. F. and M. R. Waterman (eds) (2002). Methods in Enzymology, Volume 357: Cytochrome P450, Part C. Academic Press, New York, NY.
8. Phillips, I. R. and E. A. Shephard (eds) (1998). Methods in Molecular Biology, Volume 107: Cytochrome P450 Protocols.
9. Testa, B. and P. Jenner (eds) (1976). Drug Metabolism: Chemical and Biological Aspects. Marcel Dekker.
10. Ortiz De Montellano, PR. (ed.) (1986). Cytochrome P450: Structure, Mechanism and Biochemistry. Plenum Press, New York, NY.
11. Guengerich, F. P. (ed.) (1987). Mammalian Cytochromes P450, Vols 1 & 2, CRC Press, Boca Raton, FL.
12. Schenkman, J. B. and D. Kupfer (eds) (1982). Hepatic Cytochrome P450 Monooxygenase System. Pergamon Press, Elmsford, NY.
13. Ortiz De Montellano, P. R. (ed.) (1995). Cytochrome P450: Structure, Mechanism and Biochemistry. Plenum Press, New York, NY.
14. Waxman, D. J. (1986). Rat hepatic cytochrome P-450: Comparative study of multiple isozymic forms. In PR. Ortiz de Montellano (ed.), Cytochrome P-450. Structure, Mechanism, and Biochemistry. Plenum Press, New York, NY, pp. 525-538.
15. Gonzalez, F. J. (1989). The molecular biology of cytochrome P450s. Pharmacol. Rev. 40, 243-288.
16. Guengerich, F. P. (2002). Update information on human P450s. Drug Metab. Rev. 34, 7-15.
17. Wrighton, S. A., M. Van Den Branden, J. C. Stevens, L. A. Shipley, and B. J. Ring (1993). In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab. Rev. 25, 453-484.
18. Newton, D. J., R. W. Wang, and A. Y. Lu (1995). Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes, Drug Metab. Dispos. 23, 154-158.
19. Nelson, D. R., L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman et al. (1996). P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42.
20. Guengerich, F. P. (1995). Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism and Biochemistry. Plenum Press, New York, NY, pp. 473-574.
21. Guengerich, F. P. (2004). Human cytochrome P450 enzymes. In, P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism and Biochemistry. Plenum Press, New York, NY, pp. 370-530.
22. Rendic, S. and F. J. Di Carlo (1997). Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413-580.
23. Rendic, S. (2002). Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab. Rev. 34, 83-448.
24. Kobayashi, K., K. Urashima, N. Shimada, and K. Chiba (2003). Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat. Drug Metab. Dispos. 31, 833-836.
25. Kobayashi, K., K. Urashima, N. Shimada, and K. Chiba (2002). Substrate specificity for rat cytochrome P450 (CYP) isoforms: Screening with cDNA-expressed systems of the rat. Biochem. Pharmacol. 63, 889-896.
26. Yuan, R., S. Madani, X. X. Wei, K. Reynolds, and S. M. Huang (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 30, 1311-1319.
27. Eagling, V. A., J. F. Tjia, and D. J. Back (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45, 107-114.
28. Fuhr, U, J. Doehmer, N. Battula, C. Wolfel, C. Kudla, Y. Keita et al. (1992). Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol. 43, 225-235.
29. Tassaneeyakul, W., Z. Mohamed, D. J. Birkett, M. E. McManus, M. E. Verones, R. H. Tukey et al. (1992). Caffeine as a probe for human cytochromes P450: Validation using cDNA expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2, 173-183.
30. Tassaneeyakul, W., D. J. Birkett, M. E. Veronese, M. E. McManus, R. H. Tukey, L. C. Quattrochi et al. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1 Al and 1A2. J. Pharmacol. Exp. Ther. 265, 401-407.
31. Sesardic, D., A. Boobis, B. Murray, S. Murray, J. Segura, R. De La Torre et al. (1990). Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br. J. Clin. Pharmacol. 29, 651-663.
32. Kunze, K. L. and W. F. Trager (1993). Isoformselective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656.
33. Clarke, S. E., A. D. Ayrton, and R. J. Chenery (1994). Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24, 517-526.
34. Tjia, J. F., J. Colbert, and D. J. Back (1996). Theophylline metabolism in human liver microsomes: Inhibition studies. J. Pharmacol. Exp. Ther. 276, 912-917.
35. Butler, M. N., M. Iwasaki, F. P. Guengerich, and F. K. Kadlubar (1989). Human cytochrome P-450PIA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines, Proc. Natl. Acad. Sci. USA, 86, 7696-7700.
36. Yun, C. H., G. P. Miller, and F. P. Guengerich (2000). Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 39, 11319-11329.
37. Yang, T. J., Y. Sai, K. W. Krausz, F. J. Gonzalez, and H. V. Gelboin (1998). Inhibitory monoclonal antibodies to human cytochrome P450 1A2: Analysis of phenacetin O-deethylation in human liver. Pharmacogenetics 8, 375-382.
38. Zhai, S., R. Dai, F. K. Friedman, and R. E. Vestal (1998). Comparative inhibition of human cytochrome P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos. 26, 989-992.
39. Lee, H., H. Yeom, Y. G. Kim, C. N. Yoon, C. Jin, J. S. Choi et al. (1998). Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem. Pharmacol. 55, 1369-1375.
40. Burke, M. D., S. Thompson, R. J. Weaver, C. R. Wolf, and R. T. Mayer (1994). Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48, 923-936.
41. Rodrigues, A. D. and R. A. Prough (1992). Induction of cytochromes P450IA1 and P450IA2 and measurement of catalytic activities. Meth. Enzymol. 206, 423431.
42. Yun, C. H., T. Shimada, and F. P. Guengerich (1991). Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40, 679-685.
43. Yamano, S., J. Tatsuno, and F. J. Gonzalez (1990). The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29, 1322-1329.
44. Sai, Y., T. J. Yang, K. W. Krausz, F. J. Gonzalez, and H. V. Gelboin (1999). An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics 9, 229-237.
45. Zhang, W., T. Kilicarslan, R. F. Tyndale, and E. M. Sellers (2001). Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos. 29, 897-902
46. Taavitsainen, P., R. Juvonen, and O. Pelkonen (2001). In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (Tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab. Dispos. 29, 217-222.
47. Draper, A. J., A. Madan, and A. Parkinson (1997). Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 341, 47-61.
48. Khojasteh-Bakht, S. C., L. L. Koenigs, R. M. Peter, W. F. Trager, and S. D. Nelson (1998). (R) - (+) - Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 26, 701-704.
49. Koenigs, L. L. and W. F. Trager (1998). Mechanismbased inactivation of P450 2A6 by furanocoumarins. Biochemistry 37, 10047-10061.
50. Heyn, H., R. B. White, and J. C. Stevens (1996). Catalytic role of cytochrome P450 2B6 in N-demethylation of S-mephenytion. Drug Metab. Dispos. 24, 948-954.
51. Stiborova, M., L. Borek-Dohalska, P. Hodek, J. Mraz, and E. Frei (2002). New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch. Biochem. Biophys. 403, 41-49.
52. Ekins, S., M. Van Den Branden, B. J. Ring, and S. A. Wrighton (1997). Examination of purported probes of human CYP2B6. Pharmacogenetics 7, 165-179.
53. Ekins, S. and S. A. Wrighton (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31, 719-754.
54. Rae, J. M., N. V. Soukhova, D. A. Flockhart, and Z. Desta (2002). Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: Implications for cyclophosphamide metabolism. Drug Metab. Dispos. 30, 525-530.
55. Faucette, S. R., R. L. Hawke, E. L. Lecluyse, S. S. Shord, B. Yan, R. M. Laethem et al. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28, 1222-1230.
56. Richter, T., K. Klein, T. E. Murdter, M. Eichelbaum, M. Schwab, and U. M. Zanger (2003). Clopidogrel and ticlopidine are specific mechanism-based inhibitors of human cytochrome P450 2B6. In Proceedings of the 13th International Conference on Cytochromes P450. Prague, Czech Republic, p. S119.
57. Dai, D., D. C. Zeldin, J. A. Blaisdell, B. Chanas, S. J. Coulter, B. I. Ghanayem et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid, Pharmacogenetics 11, 597-607.
58. Harris, J. W., A. Rahman, B. R. Kim, F. P. Guengerich, and J. Collins (1994). Metabolism of taxol by human hepatic microsomes and human liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035.
59. Rahman, A., K. R. Korzekwa, J. Grogan, F. J. Gonzalez, and J. W. Harris (1994). Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546.
60. Wen, X., J. S. Wang, J. T. Backman, J. Laitila, and P. J. Neuvonen (2002). Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos. 30, 631-635.
61. Wang, J. S. and C. L. De Vane (2003). Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R) - and (S)-methadone in vitro. Drug Metab. Dispos. 31, 742-747.
62. Tang, W, R. A. Stearns, R. W. Wang, S. H. Chiu, and T. A. Baillie (1999). Roles of human cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 12, 192-199.
63. Leemann, T, C. Transon, and P. Dayer (1993). Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci. 52, 29-34.
64. Rettie, A. E., K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama et al. (1992). Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59.
65. Giancarlo, G. M., K. Venkatakrishnan, B. W. Granda, L. L. Von Moltke, and D. J. Greenblatt (2001). Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol. 57, 31-36.
66. Relling, M. V, T. Aoyama, F. J. Gonzalez, and U. A. Meyer (1989). Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252, 442-447.
67. Brian, W. R., P. K. Srivastava, D. R. Umbenhauer, R. S. Lloyd, and F. P. Guengerich (1989). Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28, 4993-4999.
68. Srivastava, P. K., C. H. Yun, P. H. Beaune, C. Ged, and F. P. Guengerich (1991). Separation of human liver tolbutamine hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40, 69-79.
69. Miners, J. O. and D. J. Birkett (1996). Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Meth. Enzymol. 272, 139-145.
70. Lasker, J. M., M. R. Wester, E. Aramsombatdee, and J. L. Raucy (1998). Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylation. Arch. Biochem. Biophys. 353, 16-24.
71. Lopez-Garcia, M. P., P. M. Dansette, and D. Mansuy (1993). Thiophene derivatives as new mechanismbased inhibitors of cytochromes P450: Inactivation of yeast-expressed human liver P450 2C9 by tienilic acid. Biochemistry 33, 166-175.
72. Lopez-Garcia, M. R, P. M. Dansette, P. Valadon, C. Amar, P. H. Beaune, F. P. Guengerich et al. (1993). Human liver P450s expressed in yeast as tools for reactive metabolite formation studies: Oxidative activation of tienilic acid by P450 2C9 and P450 2C10. Eur. J. Biochem. 213, 223-232.
73. Shimada, T., K. S. Misono, and F. P. Guengerich (1986). Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J. Biol. Chem. 261, 909-921.
74. Kaminsky, L. S. (1989). Warfarin as a probe of cytochromes P450 function. Drug Metab. Rev. 20, 479-487.
75. Kaminsky, L. S., M. J. Fasco, and F. P. Guengerich (1981). Production and application of antibodies to rat liver cytochrome P-450. Meth. Enzymol. 74, 262-272.
76. Lang, D. and R. Bocker (1995). Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J. Chromatogr. Biomed. Appl. 672, 305-309.
77. Minoletti, C., S. Dijols, P. M. Dansette, and D. Mansuy (1999). Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: Application to the design of a specific substrate of CYP 2C18. Biochemistry 38, 7828-7836.
78. Ha-Duong, N. T., C. Marques-Soares, S. Dijols, M. A. Sari, P. M. Dansette, and D. Mansuy Interaction of new sulfaphenazole derivatives with human liver cytochrome P450 2Cs: Structural determinants required for selective recognition by CYP 2C9 and for inhibition of human CYP 2Cs. Arch. Biochem. Biophys. 394, 189-200.
79. Wrighton, S. A., J. C. Stevens, G. W. Becker, and M. Van Den Branden (1993). Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch. Biochem. Biophys. 306, 240-245.
80. Goldstein, J. A., M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy et al. (1994). Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 33, 1743-1752.
81. Suzuki, H., M. B. Kneller, R. L. Haining, and W. F. Trager, A. E. Rettie (2002). (+)-N-3-Benzylnirvanol and (-)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metab. Dispos. 30, 235-239.
82. Walsky, R. L. and R. S. Obach (2003). Verification of the selectivity of (+) N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab. Dispos. 31, 343.
83. Ha-Duong, NT., S. Dijols, A. C. Macherey, J. A. Goldstein, P. M. Dansette, and D. Mansuy (2001). Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40, 12112-12122.
84. Ha-Duong, N. T., S. Dijols, A. C. Macherey, P. M. Dansette, and D. Mansuy (2001). Inhibition by ticlopidine and its derivatives of human liver cytochrome P450. Mechanism-based inactivation of CYP 2C19 by ticlopidine. Adv. Exp. Med. Biol. 500, 145-148.
85. Gonzalez, F. J., T. Matsunaga, K. Nagata, U. A. Meyer, D. W. Nebert, J. Pastewka et al. (1987). Debrisoquine 4-hydroxylase: Characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 6, 149-161.
86. Gut, J., T. Catin, P. Dayer, T. Kronbach, U. Zanger, and U. A. Meyer (1986). Debrisoquine/sparteinetype polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J. Biol. Chem. 261, 11734-11743.
87. Kronbach, T. (1991). Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Meth. Enzymol. 206, 509-517.
88. Otton, S. V., T. Inaba, and W. Kalow (1984). Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 34, 73-80.
89. Bertelsen, K. M., K. Venkatakrishnan, L. L. Von Moltke, R. S. Obach, and D. J. Greenblatt (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31, 289-293.
90. Bloomer, J. C., F. R. Woods, R. E. Haddock, M. S. Lennard, and G. T. Tucker (1992). The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br. J. Clin. Pharmacol. 33, 521-523.
91. Sindrup, S. H., K. Brosen, and L. F. Gram (1992). Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51, 288-295.
92. Sindrup, S. H., K. Brosen, L. F. Gram, J. Hallas, E. Skjelbo, A. Allen et al. (1992). The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51, 278-287.
93. Dayer, P., T. Leemann, and R. Striberni (1989). Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 dbl activity. Clin. Pharmacol. Ther. 45, 34-40.
94. 14C]dextromethorphan as substrate. Meth. Enzymol. 272, 186-195.
95. Palamanda, J. R., C. N. Casciano, L. A. Norton, R. P. Clement, L. V. Favreau, C. Lin et al. (2001). Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1 H-imidazol-5-yl) methyl]-l-piperazinyl]pyrimidine. Drug Metab. Dispos. 29, 863-867.
96. Yamazaki, H., Z. Guo, and F. P. Guengerich (1995). Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab. Dispos. 23, 438-440.
97. Peter, R., R. Bocker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S. Yang (1990). Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3, 566-573.
98. Erratum in: Chem. Res. Toxicol. 4, 389, 1991.
99. Feierman, D. E. and A. I. Cederbaum (1986). Inhibition of microsomal oxidation of ethanol by pyrazole and 4-methylpyrazole in vitro. Increased effectiveness after induction by pyrazole and 4-methylpyrazole. Biochem. J. 239, 671-677.
100. Yang, C. S., C. J. Patten, H. Ishizaki, and J. S. H. Yoo (1992). Induction, purification, and characterization of cytochrome P450IIE1. Meth. Enzymol. 206, 595-603.
101. Tassaneeyakul, W., M. E. Veronese, D. J. Birkett, F. J. Gonzalez, and J. O. Miners (1993). Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol. 46, 1975-1981.
102. Guengerich, F. P., D. H. Kim, and M. Iwasaki (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179.
103. Kharasch, E. D., D. C. Hankins, C. Jubert, K. E. Thummel, and J. K. Taraday (1999). Lack of singledose disulfiram effects on cytochrome P-450 2C 9, 2C 19, 2D6, and 3A4 activities: Evidence for specificity toward P-450 2E1. Drug Metab. Dispos. 27, 717-723.
104. Chang, T. K. H., F. J. Gonzalez, and D. J. Waxman (1994). Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442.
105. Wrighton, S. A., P. E. Thomas, D. T. Molowa, M. Haniu, J. E. Shively, S. L. Maines et al. (1986). Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. Biochemistry 25, 6731-6735.
106. Yoo, J. S., F. P. Guengerich, and C. S. Yang (1988). Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res. 48, 1499-1504.
107. Yamazaki, H., Y. Inui, C. H. Yun, M. Mimura, F. R. Guengerich, and T. Shimada (1992). Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13, 1789-1794.
108. Yamazaki, H., Y. Oda, Y. Funae, S. Imaoka, Y. Inui, F. P. Guengerich et al. (1992). Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 13, 979-985.
109. Waxman, D. J., C. Attisano, F. P. Guengerich, and D. P. Lapenson (1988). Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263, 424-436.
110. Gillam, E. M., T. Baba, B. R. Kim, S. Ohmori, and F. P. Guengerich (1993). Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305, 123-131.
111. Guengerich, F. P. (1990). Mechanism-based inactivation of human liver cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3, 363-371.
112. Guengerich, F. P., M. V. Martin, P. H. Beaune, P. Kremers, T. Wolff, and D. J. Waxman (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060.
113. Gonzalez, F. J., B. J. Schmid, M. Umeno, O. W. Mcbride, J. P. Hardwick, U. A. Meyer et al. (1988). Human P450PCN1: Sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7, 79-86.
114. Guengerich, F. P, W. R. Brian, M. Iwasaki, M. A. Sari, C. Bäärnhielm, and P. Berntsson (1991). Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 II1A4. J. Med. Chem. 34, 1838-1844.
115. Varhe, A., M. B. Klaus, T. Olkkola, and P. J. Neuvonen (1994). Oral triazolam is potentially hazardous to patients receiving systemic antimycotics. Clin. Pharmacol. Then 56, 601-607.
116. Watkins, P. B., S. A. Wrighton, P. Maurel, E. G. Schuetz, G. Mendez-Picon, G. A. Parker et al. (1985). Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 82, 6310-6314.
117. Watkins, P. B., S. A. Murray, L. G. Winkelman, D. M. Heuman, S. A. Wrighton, and P. S. Guzelian (1989). Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J. Clin. Invest. 83, 688-697.
118. Thummel, K. E., C. A. Lee, K. L. Kunze, S. D. Nelson, and J. T. Slattery (1993). Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem. Pharmacol. 45, 1563-1569.
119. Renaud, J. P., C. Cullin, D. Pompon, P. Beaune, and D. Mansuy (1990). Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. Eur. J. Biochem. 194:889-896.
120. Kronbach, T., D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36, 89-96.
121. Thummel, K. E., D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, P. S. Hartwell et al. (1994). Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271, 549-556.
122. Stresser, M. D., M. I. Broudy, S. S. Dehal, C. J. Patten, and C. L. Crespi (2002). Azamulin is superior to ketoconazole as a selective CYP3A inhibitor probe. Drug Metab. Rev. Abstracts from the 11th North American 1SSX Meeting, Orlando, FL, USA, Oct. 27-Oct. 31, Vol. 34, Abs. 355, p. 178.
123. Jang, G. R., S. A. Wrighton, and L. Z. Benet (1996). Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem. Pharmacol. 52, 753-761.
124. He, K., T. F. Woolf, and P. F. Hollenberg (1999). Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J. Pharmacol. Exp. Ther. 288, 791-797.
125. Khan, K. K., Y. Q. He, M. A. Correia, and J. R. Halpert (2002). Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: Selective inactivation of P450 3A4. Drug Metab. Dispos. 30, 985-990.
126. Jones, D. R., J. C. Gorski, M. A. Hamman, B. S. Mayhew, S. Rider, and S. D. Hall (1999). Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther. 290, 1116-1125.
127. Wrighton, S. A., W. R. Brian, M. A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy et al. (1990). Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213.
128. Gillam, E. M., Z. Guo, Y. F. Ueng, H. Yamazaki, I. Cock, P. E. Reilly et al. (1995). Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys. 317, 374-384.
129. Erratum in: Arch. Biochem. Biophys. 318, 498, 1995.
130. Gorski, J. C., S. D. Hall, D. R. Jones, M. Van Den Branden, and S. A. Wrighton (1994). Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643-1653.
131. Gorski, J. C, D. R. Jones, M. A. Hamman, S. A. Wrighton, and S. D. Hall (1999). Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29, 931-944.
132. Williams, J. A., B. J. Ring, V. E. Cantrell, D. R. Jones, J. Eckstein, K. Ruterbories et al. (2002). Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30, 883-891.
133. Parimoo, B., V. M. Mishin, C. M. Busch, and P. E. Thomas (2003). Identification of epitopes on cytochrome P450 3A4/5 recognized by monoclonal antibodies. Arch. Biochem. Biophys. 414, 244-254.
134. Kitada, M., T. Kamataki, K. Itahashi, T. Rikihisa, and Y. Kanakubo (1987). P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biol. Chem. 262, 13534-13537.
135. Nakamura, H., N. Torimoto, I. Ishii, N. Ariyoshi, H. Nakasa, S. Ohmori et al. (2003). CYP3A4 and CYP3A7-mediated carbamazepine 10, 11-epoxidation are activated by differential endogenous steroids. Drug Metab. Dispos. 31, 432-438.
136. Gillam, E. M., R. M. Wunsch, Y. F. Ueng, T. Shimada, P. E. Reilly, T. Kamataki et al. (1997). Expression of cytochrome P450 3A7 in Escherichia coll. Effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 346, 81-90.
137. Kawashima, H., E. Kusunose, Y. Kikuta, H. Kinoshita, S. Tanaka, S. Yamamoto et al. (1994). Purification and cDNA cloning of human liver CYP4A fatty acid ω-hydroxylase. J. Biochem. 116, 74-80.
138. Powell, P. K., I. Wolf, and J. M. Lasker (1996). Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch. Biochem. Biophys. 335, 219-226.
139. Clarke, S. E., S. J. Baldwin, J. C. Bloomer, A. D. Ayrton, R. S. Sozio, and R. J. Chenery (1994). Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem. Res. Toxicol. 7, 836-842.
140. Amet, Y, F. Berthou, S. Baird, Y. Dreano, J. P. Bail, and J. F. Menez (1995). Validation of the (omega-1) - hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1. Biochem. Pharmacol. 50, 1775-1782.
141. Savas, U., M. H. Hsu, and E. F. Johnson (2003). Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch. Biochem. Biophys. 409, 212-220.
142. Oglivie, B. W., S. M. Otradovec, B. L. Paris, J. A. Scheinkoenig, P. W. Carrott, S. P. Loecker et al. (2000). 10-(imidazolyl)-decanoic acid (10-IDA) is a selective and potent inhibitor of CYP4A9/11. Drug. Metab. Rev. Abstracts from the 10th North American ISSX Meeting, Indianapolis, IN, USA, Vol. 32(Suppl. 2), Abs. 188, p. 230.
143. Miyata, N., K. Taniguchi, T. Seki, T. Ishimoto, M. Sato-Watanabe, Y. Yasuda et al. (2001). HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br. J. Pharmacol. 133, 325-329.
144. Powell, P. K., I. Wolf, R. Jin, and J. M. Lasker (1998). Metabolism of arachidonic acid to 20-hydroxy-5, 8, 11, 14-eicosatetraenoic acid by P450 enzymes in human liver: Involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther. 285, 1327-1336.
145. Jin, R., D. R. Koop, J. L. Raucy, and J. M. Asker (1998). Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4. Arch. Biochem. Biophys. 359, 89-98.
146. Zhang, X., L. Chen, and J. P. Hardwick (2000). Promoter activity and regulation of the CYP4F2 leukotrieneB (4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells. Arch. Biochem. Biophys. 378, 364-376.
147. Shak, S. and I. Goldstein (1984). Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. J. Biol. Chem. 259, 10181-10187.
148. Bylund, J., M. Bylund, and E. H. Oliw (2001). cDNA cloning and expression of CYP4F12, a novel human cytochrome P450. Biochem. Biophys. Res. Commun. 280, 892-897.
149. Maeda, Y. R., G. Eggertsen, B. Nyberg, T. Setoguchi, K. I. Okuda, K. Einarsson et al. (1995). Immunochemical determination of human cholesterol 7 alpha-hydroxylase. Eur. J. Biochem. 228, 144-148.
150. Gafvels, M., M. Olin, B. P. Chowdhary, T. Raudsepp, U. Andersson, B. Persson et al. (1999). Structure and chromosomal assignment of the sterol 12alpha-hydroxylase gene (CYP8B1) in human and mouse: Eukaryotic cytochrome P-450 gene devoid of introns. Genomics 56, 184-196.
151. Chun, Y. J., S. Y. Ryu, T. C. Jeong, and M. Y. Kim (2001). Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug. Metab. Dispos. 29, 389-393.
152. Guengerich, F. P., G. A. Dannan, S. T. Wright, M. V. Martin, and L. S. Kaminsky (1982). Purification and characterization of liver microsomal cytochromes P-450: Electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry 21, 6019-6030.
153. Sesardic, D., R. J. Edwards, D. S. Davies, R. E. Thomas, W. Levin, and A. R. Boobis (1990). High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. Biochem. Pharmacol. 39, 489-498.
154. Sarkar, M. A. and B. J. Jackson (1994). Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab. Dispos. 22, 827-834.
155. Chun, Y. J., S. Kim, D. Kim, S. K. Lee, and F. P. Guengerich (2001). A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61, 8164-8170.
156. Erratum in: Cancer Res. 62, 1232, 2002.
157. Shimada, T., H. Yamazaki, M. Foroozesh, N. E. Hopkins, W. L. Alworth, F. P. Guengerich (1998). Selectivity of polycyclic inhibitors for human cytochrome P450s 1A 1, 1A2, and 1B1. Chem. Res. Toxicol. 11, 1048-1056.
158. Shimada, X, F. Tsumura, E. M. Gillam, F. P. Guengerich, and K. Inoue (2000). Roles of NADPH-P450 reductase in the O-deethylation of 7-ethoxycoumarin by recombinant human cytochrome P4501B1 variants in Escherichia coli. Protein Expr. Purif. 20, 73-80.
159. Badawi, A. F., E. L. Cavalieri, and E. G. Rogan (2000). Effect of chlorinated hydrocarbons on expression of cytochrome P450 1A 1, 1A2 and 1B1 and 2- and 4-hydroxylation of 17beta-estradiol in female Sprague-Dawley rats. Carcinogenesis 21, 1593-1599.
160. Hayes, C. L., D. C. Spink, B. C. Spink, J. Q. Cao, N. J. Walker, and T. R. Sutter (1996). 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. USA 93, 9776-9781.
161. Levin, W., P. E. Thomas, D. E. Ryan, and A. W. Wood (1987). Isozyme specificity of testosterone 7α-hydroxylation in rat hepatic microsomes: Is cytochrome P-450a the sole catalyst? Arch. Biochem. Biophys. 258, 630-635.
162. Waxman, D. J., A. Ko, and C. Walsh (1983). Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 258, 11937-11947.
163. Waxman, D. J. (1988). Interactions of hepatic cytochromes P-450 with steroid hormones. Regioselectivity and stereoselectivity of steroid metabolism and hormonal regulation of rat P-450 enzyme expression. Biochem. Pharmacol. 37, 71-84.
164. 19 steroids by five highly purified and reconstituted rat hepatic cytochrome P450 isozymes. J. Biol. Chem. 258, 8839-8847.
165. Arlotto, M. P., J. M. Trant, and R. W. Estabrook (1992). Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Meth. Enzymol. 206, 454-462.
166. Smith, S. J., K. R. Korzekwa, T. Aoyama, F. J. Gonzalez, J. F. Darbyshire, K. Sugiyama et al. (1992). 12 alpha-hydroxytestosterone. A hitherto unidentified testosterone metabolite produced by cytochrome P-450 2A2. Drug Metab. Dispos. 20, 566-571.
167. Lunetta, J. M., K. Sugiyama, and M. A. Correia (1989). Secobarbital-mediated inactivation of rat liver cytochrome P-450b: A mechanistic reappraisal. Mol. Pharmacol. 35, 10-17.
168. He, K., A. M. Falick, B. Chen, F. Nilsson, and M. A. Correia (1996). Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem. Res. Toxicol. 9, 614-622.
169. Lubet, R. A., R. T. Mayer, J. W. Cameron, R. W. Nims, M. D. Burke, T. Wolff et al. (1985). Dealkylation of pentoxyresorufin: A rapid and sensitive assay for measuring induction of cytochrome (s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 238, 43-48.
170. Halpert, J., J. Y. Jaw, C. Balfour, and L. S. Kaminsky (1990). Selective inactivation by chlorofluoroacetamides of the major phenobarbital-inducible form (s) of rat liver cytochrome P-450. Drug Metab. Dispos. 18, 168-174.
171. Hopkins, N. E., M. K. Foroozesh, and W. L. Alworth (1992). Suicide inhibitors of cytochrome P450 1A1 and P450 2B1. Biochem. Pharmacol. 44, 787-796.
172. Roberts, E. S., N. E. Hopkins, M. Foroozesh, W. L. Alworth, J. R. Halpert, and P. F. Hollenberg et al. (1997). Inactivation of cytochrome P450s 2B 1, 2B 4, 2B6, and 2B11 by arylalkynes. Drug Metab. Dispos. 25, 1242-1248.
173. Swinney, D. C., D. E. Ryan, P. E. Thomas, and W. Levin (1987). Regioselective progesterone hydroxylation catalyzed by eleven rat hepatic cytochrome P-450 isozymes. Biochemistry 26, 7073-7083.
174. Halpert, J., J. Y. Jaw, and C. Balfour (1989). Specific inactivation by 17β-substituted steroids of rabbit and rat liver cytochromes P-450 responsible for progesterone 21-hydroxylation. Mol. Pharmacol. 34, 148-156.
175. Kobayashi, K., K. Urashima, N. Shimada, and K. Chiba (2003). Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat. Drug Metab. Dispos. 31, 833-836.
176. Masubuchi, Y., A. Ose, and T. Horie (2001). Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab. Dispos. 29, 1190-1195.
177. Shen, S., S. J. Hargus, B. M. Martin, and L. R. Pohl (1997). Cytochrome P4502C11 is a target of diclofenac covalent binding in rats. Chem. Res. Toxicol. 10, 420-423.
178. MacGeoch, C., E. T. Morgan, J. Halpert, and J. A. Gustafsson (1984). Purification, characterization, and pituitary regulation of the sex-specific cytochrome P-450 15 beta-hydroxylase from liver microsomes of untreated female rats. J. Biol. Chem. 259, 15433-15439.
179. Wan, J., S. Imaoka, T. Chow, T. Hiroi, Y. Yabusaki, and Y. Funae (1997). Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Arch. Biochem. Biophys. 348, 383-390.
180. Chow, T., S. Imaoka, T. Hiroi, and Y. Funae (1999). Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab. Dispos. 27, 188-192.
181. Lin, L. Y., M. Fujimoto, E. W. Distefano, D. A. Schmitz, A. Jayasinghe, and A. K. Cho (1996). Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine. J. Pharmacol. Exp. Then 277, 595-603.
182. Larrey, D., L. M. Distlerath, G. A. Dannan, G. R. Wilkinson, and F. P. Guengerich (1984). Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 23, 2787-2795.
183. Tanaka, E. (2001). Chlorzoxazone: A probe drug the metabolism of which can be used to monitor one-point blood sampling in the carbon tetrachlorideintoxicated rat. Hum. Exp. Toxicol. 20, 381-385.
184. Mizuno, D., E. Tanaka, K. Tanno, and S. Misawa (2000). Chlorzoxazone: A probe drug whose metabolism can be used to monitor toluene exposure in rats. Arch. Toxicol. 74, 139-144.
185. Mathews, J. M., A. S. Etheridge, J. H. Raymer, S. R. Black, D. W. Pulliam Jr., and J. R. Bucher (1998). Selective inhibition of cytochrome P450 2E1 in vivo and in vitro with trans-1, 2-dichloroethylene. Chem. Res. Toxicol 11, 778-785.
186. Yoo, J. S., T. J. Smith, S. M. Ning, M. J. Lee, R. E. Thomas, and C. S. Yang (1992). Modulation of the levels of cytochromes P450 in rat liver and lung by dietary lipid. Biochem. Pharmacol. 43, 2535-2542.
187. Yamazaki, H., Y. Oda, Y. Funae, S. Imaoka, Y. Inui, F. P. Guengerich et al. (1992). Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 13, 979-985.
188. Brady, J. F., H. Ishizakt, J. M. Fukuto, M. C. Lin, A. Fadel, J. M. Gapac et al. (1991). Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem. Res. Toxicol. 4, 642-647.
189. Jin, L. and T. A. Baillie (1997). Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem. Res. Toxicol. 10, 318-327.
190. Premdas, P. D., R. J. Bowers, and P. G. Forkert (2000). Inactivation of hepatic CYP2E1 by an epoxide of diallyl sulfone. J. Pharmacol. Exp. Then 293, 1112-1120.
191. Ishizaki, H., J. F. Brady, S. M. Ning, and C. S. Yang (1990). Effect of phenethyl isothiocyanate on microsomal N-nitrosodimethylamine metabolism and other monooxygenase activities. Xenobiotica 20, 255-264.
192. Sonderfan, A. J., M. P. Arlotto, D. R. Dutton, S. K. McMillen, and A. Parkinson (1987). Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255, 27-41.
193. Underwood, M. C., J. R. Cashman, and M. A. Correia (1992). Specifically designed thiosteroids as active site-directed probes for functional dissection of cytochrome P-450 3A isozymes. Chem. Res. Toxicol. 5, 42-53.
194. Wrighton, S. A., P. Maurel, E. G. Schuetz, P. B. Watkins, B. Young, and P. S. Guzelian (1985). Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry 24, 2171-2178.
195. Watkins, P. B., S. A. Wrighton, E. G. Schuetz, P. Maurel, and P. S. Guzelian (1986). Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J. Biol. Chem. 261, 6264-6271.
196. Wang, H., K. L. Napoli, and H. W. Strobel (2000). Cytochrome P450 3A9 catalyzes the metabolism of progesterone and other steroid hormones. Mol. Cell. Biochem. 213, 127-135.
197. Xue, L., V. G. Zgoda, B. Arison, and M. A. Correia (2003). Rat liver CYP3A9: Structure-function relationships to its human liver orthologs: Site-directed mutagenesis to an efficient progesterone dihydroxylase. Arch. Biochem. Biophys. 409, 113-126.
198. Gibson, G. G., T. C. Orton, and P. P. Tamburini (1982). Cytochrome P-450 induction by clofibrate: Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid). Biochem. J. 203, 161-168.
199. CaJacob, C. A., W. K. Chan, E. Shepard, and P. R. Ortiz De Montellano (1988). The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids. J. Biol. Chem. 263, 18640-18649.
200. Ortiz De Montellano, P. R. and N. O. Reich (1984). Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J. Biol. Chem. 259, 4136-1141.
201. Chiang, J. Y (1991). Reversed-phase highperformance liquid chromatography assay of cholesterol 7 alpha-hydroxylase. Meth. Enzymol. 206, 483-491.
202. Raucy, J. L., J. M. Lasker, C. S. Lieber, and M. Black (1989). Acetaminophen activation by human liver cytochromes P450IIE1 and P4501A2. Arch. Biochem. Biophys. 271, 270-283.
203. Sinclair, J., E. Jeffery, S. Wrighton, V. Kostrubsky, J. Szakacs, S. Wood, and P. Sinclair (1998). Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. Biochem. Pharmacol. 55, 1557-1565.
204. Imaoka, S., K. Inoue, and Y. Funae (1988). Aminopyrine metabolism by multiple forms of cytochrome P-450 from rat liver microsomes: Simultaneous quantitation of four aminopyrine metabolites by high-performance liquid chromatography. Arch. Biochem. Biophys. 265, 159-170.
205. Bornheim, L. M., M. C. Underwood, P. Caldera, A. E. Rettie, W. F. Trager, S. A. Wrighton et al. (1987). Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: Mechanistic implications. Mol. Pharmacol. 32, 299-308.
206. Nebert, D. W (1982). Genetic differences in the induction of monooxygenase activities by polycyclic aromatic compounds. In J. B. Schenkman and D. Kupfer (eds), Hepatic Cytochrome P-450 Monooxygenase System. Pergamon Press, New York, NY, pp. 269-291.
207. Prough, R. A., M. D. Burke, and R. T. Mayer (1978). Direct fluorometric methods for measuring mixedfunction oxidase activity. Meth. Enzymol. 52, 372-377.
208. Correia, M. A. and G. J. Mannering (1973). Reduced diphosphopyridine nucleotide synergism of the reduced triphosphopyridine nucleotide dependent mixed function oxidase of hepatic microsomes. Role of the Type I drug binding site of cytochrome P-450. Mol. Pharmacol. 9, 470-485.
209. Ortiz De Montellano, P. R. and A. K. Costa (1986). Dissociation of cytochrome P-450 inactivation and induction. Arch. Biochem. Biophys. 251, 514-524.
210. Mico, B. A., D. A. Federowicz, M. G. Ripple, and W. Kerns (1988). In vivo inhibition of oxidative drug metabolism by, and acute toxicity of 1-aminobenzotriazole (ABT). Biochem. Pharmacol. 37, 2515-2519.
211. Mugford, C. A., M. Mortillo, B. A. Mico, and J. B. Tarloff (1992). 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Fundam. Appl. Toxicol. 19, 43-49.
212. Levine, M. and G. D. Bellward (1995). Effect of cimetidine on hepatic cytochrome P450: Evidence for formation of a metabolite-intermediate complex. Drug Metab. Dispos. 23, 1407-1411.
213. Levine, M., E. Y. Law, S. M. Bandiera, T. K. Chang, and G. D. Bellward (1998). In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats. J. Pharmacol. Exp. Ther. 284, 493-199.
214. Gerber, M. C., G. A. Tejwani, N. Gerber, and J. R. Bianchine (1985). Drug interactions with cimetidine: An update. Pharmacol. Ther. 27, 353-370.
215. Smith, S. R. and M. J. Kendall (1988). Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions. Clin. Pharmacokinet. 15, 44-56.
216. Correia, M. A., C. Decker, K. Sugiyama, P. Caldera, L. Bornheim, S. A. Wrighton et al. (1987). Degradation of rat hepatic cytochrome P-450 heme by 3, 5-dicarbethoxy-2, 6-dimethyl-4-ethyl-l, 4-dihydropyridine to irreversibly bound protein adducts. Arch. Biochem. Biophys. 258, 436-451.
217. Lesca, P., E. Rafidinarivo, P. Le Cointe, and D. Mansuy (1979). A class of strong inhibitors of microsomal monooxygenases: The ellipticines. Chem. Biol. Interact. 24, 189-198.
218. Tassaneeyakul, W., D. J. Birkett, M. E. Veronese, M. E. McManus, R. H. Tukey, L. C. Quattrochi et al. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265, 401-407.
219. Hemeryck, A. and F. M. Belpaire (2002). Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr. Drug. Metab. 3, 13-37.
220. Richelson, E. (1997). Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs. Mayo Clin. Proc. 72, 835-847.
221. Letteron, P., V. Descatoire, D. Larrey, M. Tinel, J. Geneve, and D. Pessayre (1986). Inactivation and induction of cytochrome P-450 by various psoralen derivatives in rats. J. Pharmacol. Exp. Ther. 238, 685-692.
222. Koenigs, L. L. and W. F. Trager (1998). Mechanismbased inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry 37, 13184-13193.
223. Testa, B. and P. Jenner (1981). Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metab. Rev. 12, 1-117.
224. Waxman, D. J. and C. Walsh (1983). Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: Purification, characterization, and interactions with metyrapone and cytochrome b5. Biochemistry 22, 4846-4855.
225. Franklin, M. R. (1972). Inhibition of hepatic oxidative xenobiotic metabolism by piperonyl butoxide. Biochem. Pharmacol. 21, 3287-3299.
226. Hodgson, E. and R. M. Philpot (1974). Interaction of methylenedioxyphenyl (1, 3-benzodioxole) compounds with enzymes and their effects on mammals. Drug. Metab. Rev. 3, 231-301.
227. Buening, M. K. and Franklin, M. R. (1974). The formation of complexes absorbing at 455 nm from cytochrome P-450 and metabolites of compounds related to SKF 525-A. Drug Metab. Dispos. 2, 386-390.
228. Omura, T. and R. Sato (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378.
229. Estabrook, R. W., J. A. Peterson, J. Baron, and A. G. Hildebrandt (1972). The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism. In C. F. Chignell (ed.), Methods in Pharmacology, Vol. 2. Appleton-Century-Crofts, New York, NY, pp. 303-350.
230. Matsubara, T., M. Koike, A. Touchi, Y. Tochino, and K. Sugeno (1976). Quantitative determination of cytochrome P-450 in rat liver homogenate, Anal. Biochem. 75, 596-603.
231. Ryan, D. E., P. E. Thomas, D. Korzeniowski, and W. Levin (1979). Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphenyls, phenobarbital, and 3-methylcholanthrene. J. Biol. Chem. 254, 1365-1374.
232. Ryan, D. E., S. Iida, A. W. Wood, P. E. Thomas, C. S. Lieber, and W. Levin (1984). Characterization of three highly purified cytochromes P-450 from hepatic microsomes of adult male rats. J. Biol. Chem. 259, 1239-1250.
233. Ryan, D. E., P. E. Thomas, and W. Levin (1980). Hepatic microsomal cytochrome P-450 from rats treated with isosafrole. Purification and characterization of four enzymic forms. J. Biol. Chem. 255, 7941-7955.
234. Jefcoate, C. R. (1978). Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Meth. Enzymol. 52, 258-279.
235. Omura, T. and R. Sato (1964). The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J. Biol. Chem. 239, 2379-2385.
236. Elcombe, C. R., J. Bridges, R. H. Nimmo-Smith, and J. Werringloer (1975). Cumene hydroperoxidemediated formation of inhibited complexes of methylenedioxyphenyl compounds with cytochrome P450. Biochem. Soc. Trans. 3, 967-970.
237. Philpot, R. M. and E. Hodgson (1972). The effect of piperonyl butoxide concentration on the formation of cytochrome P-450 difference spectra in hepatic microsomes from mice. Mol. Pharmacol. 8, 204-214.
238. Franklin, M. R. (1977). Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacol. Ther. A. 2, 227-245.
239. Franklin, M. R. (1991). Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Meth. Enzymol. 206, 559-573.
240. Larrey, D., M. Tinel, and D. Pessayre (1983). Formation of inactive cytochrome P-450 Fe (II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem. Pharmacol. 32, 1487-1493.
241. Delaforge, M., E. Sartori, and D. Mansuy (1988). In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450: Comparison with troleandomycin and erythromycin. Chem. Biol. Interact. 68, 179-188.
242. Paul, K. G., H. Theorell, and A. Akeson (1953). The molar light absorption of pyridine ferroprotoporphyrin (Pyridine Haemochromogen). Acta. Chem. Scand. 7, 1284-1287.
243. Waterman, M. R. (1978). Spectral characterization of human hemoglobin and its derivatives. Meth. Enzymol. 52, 456-463.
244. Klingenberg, M. (1958). Pigments of rat liver microsomes. Arch. Biochem. Biophys. 75, 376-386.
245. 5. J. Biol. Chem. 235, 2492-2497.
246. 5. Meth. Enzymol. 52, 97-101.
247. Guengerich, F. P. (1994). Analysis and characterization of enzymes. In A. W. Hayes (ed.), Principles and Methods of Toxicology. Raven Press, Ltd., New York, NY. pp. 1259-1313.
248. Phillips, A. H. and R. G. Langdon (1962). Hepatic triphosphopyridine nucleotide-cytochrome c reductase: Isolation, characterization, and kinetic studies. J. Biol. Chem. 237, 2652-2660.
249. Strobel, H. W and J. D. Dignam (1978). Purification and properties of NADPH-cytochrome P-450 reductase. Meth. Enzymol. 52, 89-96.
250. Wang, H., R. Dick, H. Yin, E. Licad-Coles, D. Kroetz, G. Szklarz et al. (1998). Structure-function relationships of human liver cytochromes P450 3A: Aflatoxin B1 metabolism as a probe. Biochemistry 37, 12536-12545.